key: cord-0777826-rq7kftoy
authors: Agaronov, A.; Makdesi, C.; Hall, C.
title: Acute Generalized Exanthematous Pustulosis Induced by Moderna COVID-19 mRNA Vaccine
date: 2021-08-27
journal: JAAD Case Rep
DOI: 10.1016/j.jdcr.2021.08.013
sha: e0ca6bcc34d5760a7e52dc4cbf4335fcd2460168
doc_id: 777826
cord_uid: rq7kftoy

nan

penetrates the cell membrane into the cytosol and produces a spike protein for subsequent 7 antigen presentation and immune system activation. 1 Although this vaccine technology is 8 presumed to be safe through clinical trials, the full spectrum of adverse effects of mRNA 9 vaccines has not yet been characterized. Nonetheless, a wide range of cutaneous adverse effects 

AGEP is a rare skin eruption characterized by an acute onset of numerous small, non-follicular 32 sterile pustules on an erythematous base. Clinically, AGEP is characterized by fever, with skin 33 lesions typically beginning on the face or intertriginous zones (i.e., axillae, groin, inframammary 34 folds) before disseminating over a few hours. Pruritus may also be present. Lesions normally last 35 1 to 2 weeks followed by superficial desquamation. More than 90% of cases of AGEP are due to 36 Currently, AGEP is a seemingly rare cutaneous adverse effect following the Pfizer BioNTech 54

and Moderna COVID-19 mRNA vaccines. As more of the population receives the vaccine, it is 55 likely that more individuals will develop cutaneous adverse effects, with AGEP and AGEP-like 56 pustular eruptions potentially being reported more frequently. It is important for clinicians to be 57 aware of this entity in their COVID-19 vaccinated patients as it will allow more prompt 58 diagnosis and appropriate evaluation to exclude more serious cutaneous reactions. Further 59 studies will need to be done to discover the significance of this dermatologic finding in the 

Non-viral COVID-19 vaccine delivery systems

Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A 73 registry-based study of 414 cases

Neutrophilic Drug Eruptions

Acute 78 generalized exanthematous pustulosis induced by parvovirus b19 infection

Acute generalized exanthematous pustulosis with 82 cytomegalovirus infection

Acute generalized exanthematous 85 pustulosis due to Coxsackie B4 virus

Acute generalized 87 exanthematous pustulosis after COVID-19 treatment with hydroxychloroquine

Delayed Presentation of Acute Generalized 90

Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-91 19 without the Use of Hydroxychloroquine

Late-onset AGEP-like skin pustular 94 eruption following COVID-19: A possible association

Cutaneous manifestation of

-2 infection: a clinical update